Literature DB >> 21215812

Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells.

J Joseph Melenhorst1, Phillip Scheinberg, Ann Williams, David R Ambrozak, Keyvan Keyvanfar, Melody Smith, J Philip McCoy, Nancy F Hensel, Daniel C Douek, A John Barrett.   

Abstract

T cell responses to allogeneic targets arise predominantly from the naïve pool. However, in humans, the risk of graft-versus-host disease is increased if the donor has circulating T cells recognizing multiple persistent DNA viruses, suggesting that memory T cells also contribute to the alloresponse. To examine HLA alloreactivity, we used flow cytometry-based proliferation and cytokine production assays. We identified the clonal identity of virus-specific T cells cross-reacting with HLA-disparate targets by sequencing the T cell receptor β chains in virus-specific T cell lines restimulated with cognate and HLA-disparate targets and sorting these chains according to cytokine response. We confirmed that naïve T cells from cord blood and adult individuals responded to HLA-mismatched target cells. In addition, in adults, we identified memory T cells responding by cytokine release to HLA-mismatched targets both in direct assays and after 8 days of culture with allogeneic stimulator cells. Epstein-Barr virus-specific and cytomegalovirus-specific T cells, tested against a panel of 30 T cell antigen-presenting cells with a broad coverage of the most prominent HLA types, displayed specificity for certain mismatched HLA alleles. Sequencing of the T cell receptor β chain demonstrated a clonotypic identity of cells that responded to both viral and allogeneic stimulation. These findings show conclusively that alloresponses in humans are not confined to the naïve T cell subset, and that memory viral antigen-specific T cells can cross-react with specific mismatched HLA-peptide complexes not presenting with cytomegalovirus or Epstein-Barr virus peptides. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21215812      PMCID: PMC3100442          DOI: 10.1016/j.bbmt.2010.12.711

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  58 in total

1.  Coexistent naïve phenotype and higher cycling rate of cord blood T cells as compared to adult peripheral blood.

Authors:  Paul Szabolcs; Kyung-Duk Park; Melissa Reese; Luciana Marti; Gloria Broadwater; Joanne Kurtzberg
Journal:  Exp Hematol       Date:  2003-08       Impact factor: 3.084

2.  EBV-specific CD4+ T cell clones exhibit vigorous allogeneic responses.

Authors:  Elise Landais; Alexis Morice; Heather M Long; Tracey A Haigh; Béatrice Charreau; Marc Bonneville; Graham S Taylor; Elisabeth Houssaint
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

3.  The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire.

Authors:  Batoul Pourgheysari; Naeem Khan; Donna Best; Rachel Bruton; Laxman Nayak; Paul A H Moss
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

4.  Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells.

Authors:  Jason M Brenchley; Nitin J Karandikar; Michael R Betts; David R Ambrozak; Brenna J Hill; Laura E Crotty; Joseph P Casazza; Janaki Kuruppu; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

5.  Hyperacute GVHD: risk factors, outcomes, and clinical implications.

Authors:  Rima M Saliba; Marcos de Lima; Sergio Giralt; Borje Andersson; Issa F Khouri; Chitra Hosing; Shubhra Ghosh; Joyce Neumann; Yvonne Hsu; Jorge De Jesus; Muzaffar H Qazilbash; Richard E Champlin; Daniel R Couriel
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

6.  Cross-recognition of human alloantigen by cytomegalovirus glycoprotein-specific CD4+ cytotoxic T lymphocytes: implications for graft-versus-host disease.

Authors:  Rebecca Elkington; Rajiv Khanna
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

7.  Co-recognition of endogenous antigens with HLA-DR1 by alloreactive human T cell clones.

Authors:  G Lombardi; S Sidhu; J R Lamb; J R Batchelor; R I Lechler
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

8.  Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia.

Authors:  Hong Zheng; Catherine Matte-Martone; Dhanpat Jain; Jennifer McNiff; Warren D Shlomchik
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

Review 9.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

Authors:  Andrew D Hislop; Graham S Taylor; Delphine Sauce; Alan B Rickinson
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

10.  Cross-reactivity of self-HLA-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes for allo-HLA determinants.

Authors:  J S Gaston; A B Rickinson; M A Epstein
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

View more
  12 in total

1.  Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.

Authors:  Jan J Melenhorst; Paul Castillo; Patrick J Hanley; Michael D Keller; Robert A Krance; Judith Margolin; Ann M Leen; Helen E Heslop; A John Barrett; Cliona M Rooney; Catherine M Bollard
Journal:  Mol Ther       Date:  2014-09-30       Impact factor: 11.454

2.  Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.

Authors:  Greg D Whitehill; Shoba Amarnath; Pawel Muranski; Keyvan Keyvanfar; Minoo Battiwalla; Austin J Barrett; Dhanalakshmi Chinnassamy
Journal:  Mol Ther       Date:  2016-07-06       Impact factor: 11.454

Review 3.  Graft versus tumor effects and why people relapse.

Authors:  J H Frederik Falkenburg; Inge Jedema
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host disease.

Authors:  Gerald P Morris; Geoffrey L Uy; David Donermeyer; John F Dipersio; Paul M Allen
Journal:  Sci Transl Med       Date:  2013-06-05       Impact factor: 17.956

5.  Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Authors:  Marie Bleakley; Shelly Heimfeld; Lori A Jones; Cameron Turtle; Diane Krause; Stanley R Riddell; Warren Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-11       Impact factor: 5.742

Review 6.  Allo-reactive T cells for the treatment of hematological malignancies.

Authors:  J H F Falkenburg; I Jedema
Journal:  Mol Oncol       Date:  2015-10-24       Impact factor: 6.603

7.  Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Authors:  Alana A Kennedy-Nasser; Stephanie Ku; Paul Castillo-Caro; Yasmin Hazrat; Meng-Fen Wu; Hao Liu; Jos Melenhorst; A John Barrett; Sawa Ito; Aaron Foster; Barbara Savoldo; Eric Yvon; George Carrum; Carlos A Ramos; Robert A Krance; Kathryn Leung; Helen E Heslop; Malcolm K Brenner; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2014-02-26       Impact factor: 12.531

8.  Activation-induced CD137 is a fast assay for identification and multi-parameter flow cytometric analysis of alloreactive T cells.

Authors:  N H R Litjens; E A de Wit; C C Baan; M G H Betjes
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

Review 9.  Alloreactivity of virus-specific T cells: possible implication of graft-versus-host disease and graft-versus-leukemia effects.

Authors:  Shigeo Fuji; Markus Kapp; Hermann Einsele
Journal:  Front Immunol       Date:  2013-10-14       Impact factor: 7.561

10.  Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions.

Authors:  Nicholas Brodszki; Dominik Turkiewicz; Jacek Toporski; Lennart Truedsson; Josefina Dykes
Journal:  Orphanet J Rare Dis       Date:  2016-01-15       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.